Grey Wolf Animal Health Corp
Grey Wolf Animal Health Corp operates in the retail sector, specializing in the sale of animal health products and services, primarily generating revenue through direct sales to consumers.
Business. Grey Wolf Animal Health Corp (WOLF.V) is a miscellaneous specialty retailer operating within the consumer cyclicals sector. The company generates revenue through the sale of products, with its primary listing on the TSX Venture exchange. Specific details regarding operating segments and geographic presence are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-08-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Grey Wolf Animal Health Corp (WOLF.V) is a miscellaneous specialty retailer operating within the consumer cyclicals sector. The company generates revenue through the sale of products, with its primary listing on the TSX Venture exchange. Specific details regarding operating segments and geographic presence are not disclosed in the available data.
Grey Wolf Animal Health Corp maintains a capital structure with a debt-to-equity ratio of 0.38, indicating a relatively conservative leverage position compared to the industry median. The company's liquidity position is characterized by a current ratio of 3.17, suggesting strong short-term liquidity. However, the operating cash flow is negative at -1,812,690 CAD, which may raise concerns about the company's ability to sustain operations without external financing.
In terms of profitability, the company's return on equity (ROE) is 0.5%, and return on assets (ROA) is 0.33%, both of which are below the industry median for profitability metrics. The net income of 126,070 CAD and operating income of 291,150 CAD indicate modest profitability, with a gross profit margin of 51.47% (3,112,160 CAD / 6,046,510 CAD revenue). These figures suggest that the company is not outperforming its peers in terms of generating returns on invested capital.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher risks if demand in its primary market fluctuates. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets or product lines.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The current fiscal year's revenue is 6,046,510 CAD, and there is no indication of a significant increase in the next fiscal year. The company's capital expenditure of -52,820 CAD suggests minimal investment in new projects or expansion, which may limit future growth opportunities.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could necessitate additional financing. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares. The valuation adjustments applied in the custom valuations do not indicate significant overvaluation or undervaluation.
There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The absence of recent transcripts or filings suggests that the company may not be actively communicating with investors or disclosing material developments.
- Grey Wolf Animal Health Corp has a conservative debt-to-equity ratio of 0.38, indicating a relatively low leverage position.
- The company's ROE and ROA are below the industry median, suggesting that it is not generating strong returns on invested capital.
- The company's revenue is concentrated in a single segment, with no geographic diversification disclosed, which may increase its exposure to market-specific risks.
- The company's growth trajectory is uncertain, with no significant capital expenditure and no clear revenue growth projections.
- The company faces a medium liquidity risk due to a negative operating cash flow and a low dilution risk as the number of shares outstanding remains unchanged.
- **margin_outlook_rationale**: The company's gross profit margin is 51.47%, but the net income margin is only 2.09%, indicating that operating expenses are eroding profitability.
- **rd_outlook_rationale**: There is no specific information provided about the company's research and development activities or their impact on future profitability.
Bull / Bear case
Generated · model-assistedRevenue grew 33.3% year-over-year to CAD 35.8 million, demonstrating strong top-line expansion momentum.
Net income surged 135.1% to CAD 1.66 million, indicating significant improvement in overall profitability.
Operating income increased 112.9% to CAD 4.06 million, reflecting substantial gains in core operational efficiency.
Free cash flow rose 126.0% to CAD 3.84 million, highlighting robust cash generation capabilities.
Operating margin of 4.8% exceeds the 3.9% median for Miscellaneous Specialty Retailers peers.
High credit risk and a current ratio of 0.36 signal severe short-term liquidity constraints.
Cash conversion ranks in the bottom quartile of the peer group, indicating inefficient cash management.
Medium liquidity risk flags potential challenges in meeting immediate financial obligations despite recent growth.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- 10% owner · Equity Swap (obligation to sell) → Common Stock, $0.00125 par valueAcquired 883 924 @ $26,12other · 2025-10-30
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Grey Wolf Animal Health Corp Market data — financials · 2026-05-30
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,37 %$6M
- Institutional Investor · as of 2022-09-300,01 %$0M
- Investment Managers · as of 2026-03-310,00 %$70M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2026-03-310,00 %$14M
- Investment Managers · as of 2026-03-310,00 %$8M
- Institutional Investor · as of 2026-03-310,00 %$26M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2024-06-300,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$6M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Chief Operating Officer · COMMON STOCKOther 3 299 @ $35,10$116K · 2026-07-15
- Director, CEO and Director · COMMON STOCKOther 8 247 @ $35,10$289K · 2026-07-15
- EVP Chief Legal/Global Affairs · COMMON STOCKOther 38 775 · 2026-07-01
- Director, CEO and Director · COMMON STOCKOther 29 307 @ $36,76$1,1M · 2026-05-01
- Director · COMMON STOCKOther 31 732 · 2025-12-17
- Director · COMMON STOCKOther 31 732 · 2025-12-17
- Director · COMMON STOCKOther 31 732 · 2025-12-17
- Director · COMMON STOCKOther 31 732 · 2025-12-17
- Director · COMMON STOCKOther 31 732 · 2025-12-17
- Director · COMMON STOCKOther 31 732 · 2025-12-17
- CFO & Executive Vice President · COMMON STOCKOther 172 263 · 2025-12-08
- Chief Operating Officer · COMMON STOCKOther 126 931 · 2025-12-08
- Director, CEO and Director · COMMON STOCKOther 317 327 · 2025-12-08
- 10% owner · Common Stock, $0.00125 par valueSold 194 423 @ $26,18$5,1M · 2025-10-31
- 10% owner · Common Stock, $0.00125 par valueBought 24 773 @ $26,67$661K · 2025-10-31
- 10% owner · Common Stock, $0.00125 par valueBought 53 530 @ $27,46$1,5M · 2025-10-31
- 10% owner · Common Stock, $0.00125 par valueBought 116 002 @ $26,12$3,0M · 2025-10-30
- Chief Operating Officer · COMMON STOCKOther 21 300 · 2025-09-29
- Chief Operating Officer · COMMON STOCKOther 178 · 2025-09-29
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-28 vs 2024-12-29): 68.4%Derived (calculated)
- Total assets (YoY) (2025-12-28 vs 2024-12-29): -55.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-28 vs 2024-12-29): 67.6%Derived (calculated)
- Current ratio (FY 2025-12-28): 6.50xDerived (calculated)
- Debt-to-equity (FY 2025-12-28): 4.49xDerived (calculated)
- Long-term debt (YoY) (2025-12-28 vs 2024-12-29): -69.4%Derived (calculated)
- Shares outstanding (annual): 27.36MSEC XBRL filing
- Total assets (annual): USD 3.45BSEC XBRL filing
- Current assets (annual): USD 1.93BSEC XBRL filing
- Total liabilities (annual): USD 2.82BSEC XBRL filing
- Current liabilities (annual): USD 297.1MSEC XBRL filing
- Shareholders' equity (annual): USD 627.4MSEC XBRL filing
- Cash & equivalents (annual): USD 1.03BSEC XBRL filing
- Long-term debt (annual): USD 1.96BSEC XBRL filing
- EPS (basic) (YoY) (2025-06-29 vs 2023-06-25): -329.8%Derived (calculated)
- Net margin (FY 2025-06-29): -212.4%Derived (calculated)
- Gross margin (FY 2025-06-29): -16.1%Derived (calculated)
- Capex (YoY) (2025-06-29 vs 2023-06-25): 33.9%Derived (calculated)
- Cost of revenue (YoY) (2025-06-29 vs 2023-06-25): 70.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-06-29 vs 2023-06-25): -329.8%Derived (calculated)
- Gross profit (YoY) (2025-06-29 vs 2023-06-25): -150.1%Derived (calculated)
- Net income (YoY) (2025-06-29 vs 2023-06-25): -387.8%Derived (calculated)
- Operating cash flow (YoY) (2025-06-29 vs 2023-06-25): -399.1%Derived (calculated)
- Operating income (YoY) (2025-06-29 vs 2023-06-25): -326.3%Derived (calculated)